Drug makers have adopted or suggested a plethora of payment models for ensuring coverage of cell and gene therapies. But while they address the general question of how to pay for one-time therapies with exceptionally high upfront price tags, one issue that remains is how to factor in the availability of only short-term data.
“I think there’s a tremendous opportunity for long-term, outcomes-based and/or payment-over-time models to serve as that bridge and address that...